Drugs & Targets FDA grants Augtyro priority review for NTRK-positive locally advanced or metastatic solid tumors February 16, 2024Vol.50 No.07
Regulatory News FDA tells sponsors of CAR T-cell therapies to add boxed warning about secondary T-cell malignancies February 02, 2024Vol.50 No.05By Alexandria Carolan
Guest Editorial Reflecting on Janet Woodcock’s retirement from FDA January 26, 2024Vol.50 No.04By Ellen V. Sigal
Drugs & Targets FDA approves Balversa for locally advanced or metastatic urothelial carcinoma January 26, 2024Vol.50 No.04
In Brief Kelly Norsworthy named acting associate director for research mentorship in FDA’s Oncology Center of Excellence January 19, 2024Vol.50 No.03
Drugs & Targets FDA approves Keytruda + chemoradiotherapy for FIGO 2014 stage 3-4A cervical cancer January 19, 2024Vol.50 No.03
Regulatory News Heated discussion breaks out in recent meeting as FDA mulls standards for MCD approvalMeanwhile, NCI trial will assess clinical utility January 12, 2024Vol.50 No.02By Jacquelyn Cobb
Drugs & Targets FDA approves Padcev + Keytruda for locally advanced or metastatic urothelial cancer January 05, 2024Vol.50 No.01
